BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 2021;14:121. [PMID: 34372899 DOI: 10.1186/s13045-021-01111-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Yi M, Zhang D, Song B, Zhao B, Niu M, Wu Y, Dai Z, Wu K. Increased expression of ECT2 predicts the poor prognosis of breast cancer patients. Exp Hematol Oncol 2022;11:107. [PMID: 36572949 DOI: 10.1186/s40164-022-00361-3] [Reference Citation Analysis]
2 Zhao H, Wei Z, Shen G, Chen Y, Hao X, Li S, Wang R. Poly(rC)-binding proteins as pleiotropic regulators in hematopoiesis and hematological malignancy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1045797] [Reference Citation Analysis]
3 Li Y, Azmi AS, Mohammad RM. Deregulated transcription factors and poor clinical outcomes in cancer patients. Semin Cancer Biol 2022;86:122-34. [PMID: 35940398 DOI: 10.1016/j.semcancer.2022.08.001] [Reference Citation Analysis]
4 Donati G, Amati B. MYC and therapy resistance in cancer: risks and opportunities. Mol Oncol 2022;16:3828-54. [PMID: 36214609 DOI: 10.1002/1878-0261.13319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Othman NS, Mohd Azman DK. Andrographolide Induces G2/M Cell Cycle Arrest and Apoptosis in Human Glioblastoma DBTRG-05MG Cell Line via ERK1/2 /c-Myc/p53 Signaling Pathway. Molecules 2022;27:6686. [PMID: 36235222 DOI: 10.3390/molecules27196686] [Reference Citation Analysis]
6 Anatskaya OV, Vinogradov AE. Polyploidy and Myc Proto-Oncogenes Promote Stress Adaptation via Epigenetic Plasticity and Gene Regulatory Network Rewiring. IJMS 2022;23:9691. [DOI: 10.3390/ijms23179691] [Reference Citation Analysis]
7 Liu G, Li D, Zhang L, Xu Q, Zhuang D, Liu P, Hu L, Deng H, Sun J, Wang S, Zheng B, Guo J, Wu X. Phenformin Down-Regulates c-Myc Expression to Suppress the Expression of Pro-Inflammatory Cytokines in Keratinocytes. Cells 2022;11:2429. [PMID: 35954273 DOI: 10.3390/cells11152429] [Reference Citation Analysis]
8 Wu T, Wang W, Shi G, Hao M, Wang Y, Yao M, Huang Y, Du L, Zhang X, Ye D, Bian X, Wang J. Targeting HIC1/TGF-β axis-shaped prostate cancer microenvironment restrains its progression. Cell Death Dis 2022;13:624. [PMID: 35853880 DOI: 10.1038/s41419-022-05086-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Hu S. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathol Oncol Res 2022;28:1610447. [DOI: 10.3389/pore.2022.1610447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Huang M, Liu C, Shao Y, Zhou S, Hu G, Yin S, Pu W, Yu H. Anti-tumor pharmacology of natural products targeting mitosis. Cancer Biol Med 2022:j. [PMID: 35699421 DOI: 10.20892/j.issn.2095-3941.2022.0006] [Reference Citation Analysis]
11 He M, Cao C, Ni Z, Liu Y, Song P, Hao S, He Y, Sun X, Rao Y. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther 2022;7:181. [PMID: 35680848 DOI: 10.1038/s41392-022-00999-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. Int J Mol Sci 2022;23:2919. [PMID: 35328342 DOI: 10.3390/ijms23062919] [Reference Citation Analysis]
13 Wu PS, Wang CY, Chen PS, Hung JH, Yen JH, Wu MJ. 8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells. Biomedicines 2021;9:1907. [PMID: 34944720 DOI: 10.3390/biomedicines9121907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Perez-Chacon G, Vincent-Fabert C, Zapata JM. Editorial: Mouse Models of B Cell Malignancies. Front Immunol 2021;12:789901. [PMID: 34777400 DOI: 10.3389/fimmu.2021.789901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Valikhani M, Rahimian E, Ahmadi SE, Chegeni R, Safa M. Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment. Exp Hematol Oncol 2021;10:51. [PMID: 34732266 DOI: 10.1186/s40164-021-00242-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M. Correction to: MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 2021;14:135. [PMID: 34474678 DOI: 10.1186/s13045-021-01152-9] [Reference Citation Analysis]